| Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial PB Gilbert, DC Montefiori, AB McDermott, Y Fong, D Benkeser, W Deng, ... Science 375 (6576), 43-50, 2022 | 913 | 2022 |
| Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition L Corey, PB Gilbert, M Juraska, DC Montefiori, L Morris, ST Karuna, ... New England Journal of Medicine 384 (11), 1003-1014, 2021 | 327 | 2021 |
| Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial BO Taiwo, VC Marconi, B Berzins, CB Moser, AN Nyaku, CJ Fichtenbaum, ... Clinical Infectious Diseases 66 (11), 1794-1797, 2018 | 124 | 2018 |
| Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized … MP O’Brien, E Forleo-Neto, N Sarkar, F Isa, P Hou, KC Chan, BJ Musser, ... Jama 327 (5), 432-441, 2022 | 98 | 2022 |
| ACTG A5353: a pilot study of dolutegravir plus lamivudine for initial treatment of human immunodeficiency virus-1 (HIV-1)–infected participants with HIV-1 RNA< 500000 copies/mL BO Taiwo, L Zheng, A Stefanescu, A Nyaku, B Bezins, CL Wallis, ... Clinical Infectious Diseases 66 (11), 1689-1697, 2018 | 93 | 2018 |
| Long-acting antiretrovirals: where are we now? AN Nyaku, SG Kelly, BO Taiwo Current HIV/AIDS Reports 14, 63-71, 2017 | 69 | 2017 |
| Inclusion and diversity in clinical trials: actionable steps to drive lasting change MD Kelsey, B Patrick-Lake, R Abdulai, UC Broedl, A Brown, E Cohn, ... Contemporary clinical trials 116, 106740, 2022 | 56 | 2022 |
| Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms PC Treitler, CF Bowden, J Lloyd, M Enich, AN Nyaku, S Crystal Journal of substance abuse treatment 132, 108514, 2022 | 51 | 2022 |
| Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA< 500 000 copies/mL: week 48 outcomes from ACTG 5353 AN Nyaku, L Zheng, RM Gulick, M Olefsky, B Berzins, CL Wallis, ... Journal of Antimicrobial Chemotherapy 74 (5), 1376-1380, 2019 | 30 | 2019 |
| Two-drug treatment approaches in HIV: finally getting somewhere? SG Kelly, AN Nyaku, BO Taiwo Drugs 76, 523-531, 2016 | 25 | 2016 |
| No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial JZ Li, PE Sax, VC Marconi, J Fajnzylber, B Berzins, AN Nyaku, ... Open forum infectious diseases 6 (3), ofz056, 2019 | 23 | 2019 |
| ACTG A5353: a pilot study of dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA< 500,000 copies/mL BO Taiwo, L Zheng, A Stefanescu, A Nyaku, B Bezins, CL Wallis Clin Infect Dis 66 (11), 1689-1697, 2018 | 15 | 2018 |
| Determinants of HIV phylogenetic clustering in Chicago among young black men who have sex with men from the uConnect cohort E Morgan, AN Nyaku, TD Richard, JA Schneider JAIDS Journal of Acquired Immune Deficiency Syndromes 75 (3), 265-270, 2017 | 14 | 2017 |
| Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS) EN Waddell, SA Springer, LA Marsch, D Farabee, RP Schwartz, A Nyaku, ... Journal of substance abuse treatment 128, 108389, 2021 | 13 | 2021 |
| ACTG A5353: a pilot study of dolutegravir (DTG)+ lamivudine (3TC) for initial treatment of HIV-1-infected participants with HIV-1 RNA< 500,000 copies/mL BO Taiwo, L Zheng, AN Nyaku, A Stefanescu, PE Sax, D Haas 9th IAS Conference on HIV Science (IAS 2017), 23-26, 2017 | 11 | 2017 |
| Clinical and demographic factors associated with COVID-19, severe COVID-19, and SARS-CoV-2 infection in adults: a secondary cross-protocol analysis of 4 randomized clinical trials DA Theodore, AR Branche, L Zhang, DS Graciaa, M Choudhary, ... JAMA network open 6 (7), e2323349-e2323349, 2023 | 9 | 2023 |
| Comparisons of injection and non-injection opioid use among Black people in methadone treatment: A pilot in Detroit CA Struble, JJ Lister, J Urbiel, AN Nyaku, CL Arfken Addictive behaviors 126, 107182, 2022 | 5 | 2022 |
| Comparison of HIV testing uptake in an urban academic emergency department using different testing assays and support systems AN Nyaku, LM Williams, SR Galvin AIDS patient care and STDs 30 (4), 166-169, 2016 | 5 | 2016 |
| Risk of COVID-19 after natural infection or vaccination AM Rick, MB Laurens, Y Huang, C Yu, TCS Martin, CA Rodriguez, ... EBioMedicine 96, 2023 | 4 | 2023 |
| Prior case of resistance on dolutegravir plus lamivudine dual therapy BO Taiwo, ME Quiñones-Mateu, K Smith, L Zheng, R Gulick, AN Nyaku, ... AIDS research and human retroviruses 36 (4), 254, 2020 | 3 | 2020 |
